Genmab A (GMAB) Revenue Growth (1y) (2019 - 2026)
Powered by 
Analysis
Genmab A (GMAB) Revenue Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 9.53% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 10.18% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 12.45% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 16.73% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 2.11% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 59.71% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 66.86% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 3.42% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | -29.57% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -29.57% |
| Mar 31, 2026 | 25.31% |
| Sep 30, 2025 | 21.11% |
| Jun 30, 2025 | 18.67% |
| Mar 31, 2025 | 18.57% |
| Sep 30, 2024 | -53.67% |
| Jun 30, 2022 | 37.66% |
| Dec 31, 2021 | -64.81% |
| Sep 30, 2021 | 133,990,619.26% |
| Jun 30, 2021 | -58.39% |
| Dec 31, 2020 | 60,888,666.80% |
| Sep 30, 2020 | -100.00% |
| Jun 30, 2020 | 586.49% |
| Dec 31, 2019 | -100.00% |